ArticlePLoS pathogens2021

Intranasal type I interferon treatment is beneficial only when administered before clinical signs onset in the SARS-CoV-2 hamster model.

Pierre Bessière et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.